Galapagos To Present New Preliminary Translational Data And Previously Disclosed Data From EUPLAGIA-1 Phase 1/2 Study At The European Society For Blood And Marrow Transplantation - 8K

Author: Benzinga Newsdesk | February 16, 2024 07:10am

The preliminary translational data demonstrate that Galapagos’ differentiated point-of-care manufacturing platform offers the potential for a single infusion of fresh early-phenotype CD19 CAR-T cells with robust expansion and persistence in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL) and patients with Richter transformation (RT). Further, previously disclosed safety, efficacy and feasibility data from EUPLAGIA-1 and ATALANTA-1 support the potential of Galapagos’ innovative approach to CAR-T manufacturing and of the transformational impact on patients with severe hematologic cancers.

Posted In: GLPG